Pieris Pharmaceuticals - Gilde Healthcare

Pieris Pharmaceuticals


Freising, Germany

Protein Therapeutics
Since: 2002
Exit: 2014

Pieris Pharmaceuticals is a clinical-stage biopharmaceutical company dedicated to the discovery and development of its proprietary Anticalin® class of biotherapeutics. The company  has successfully developed a clinical-stage pipeline and closed commercial collaboration with firms like Daiichi Sankyo, Sanofi Pasteur and Allergan.

Pieris Pharmaceuticals began trading on the OTC Markets on December 18, 2014 and later at NASDAQ (Nasdaq: PIRS) on June 30, 2015.

Pieris is located in Boston and in the Munich area (Germany).


More Pieris Pharmaceuticals news

Pieris Pharmaceuticals Prices Public Offering of Common Stock

Pieris Pharmaceuticals, Inc. Goes Public, Raises $12.2 Million

Pieris Achieves Second Milestone Payment in Daiichi Sankyo Collaboration to Develop Anticalin®

Pieris and Sanofi Broaden Existing Collaboration

Pieris Achieves First Milestone Payment in Daiichi Sankyo Collaboration to Develop Anticalin®

Pieris Presents Preclinical Data for PRS-110 c-Met Antagonist Anticalin at the AACR Annual Meeting

Pieris Receives EUR 6 million Grant to Novel Anticalin Therapeutic to Treat Anemia

Pieris signs major collaboration with Daiichi Sankyo

Pieris to Present Interim Data from the Phase I Clinical Trial of PRS-050 at Molecular Medicine

Takeda San Francisco and Pieris Sign Anticalin® Therapeutic Collaboration

Pieris signs broad collaboration with Sanofi

Pieris Initiates Phase I Clinical Trial for Lead Anticalin Compound

Pieris AG Appoints Chief Scientific Officer

PIERIS Announces Positive Preclinical Data on c-Met Anticalin Drug Program

Pieris Appoints a New CEO

Pieris AG enters into Anticalin Collaboration with Allergan, Inc.

PIERIS reports development progress for Anticalin® PRS-050, a next generation VEGF antagonist

PIERIS – Wacker Validates Scalability of Anticalin(R) Production With E.coli Secretion Technology

Pieris Raises EUR 25 million in Series B Financing Round